Načítá se...
Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer
SUMMARY: In women with estrogen receptor(ER)- and ErbB2 (HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance. As such, co-targeting ErbB1 and ErbB2 with la...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
S. Karger GmbH
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2931095/ https://ncbi.nlm.nih.gov/pubmed/20847831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000285775 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|